Stockscreener 앱 받기
6.94
2.06%
0.14
시간 외 거래:
6.94
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - The Manila Times
Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily
Will Aligos Therapeutics Inc. benefit from current market trends2025 Stock Rankings & AI Forecast Swing Trade Picks - mfd.ru
What are the future prospects of DWSNMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Aligos Therapeutics Inc. weather a recessionMarket Weekly Review & Daily Profit Maximizing Trade Tips - mfd.ru
Rally Mode: What analysts say about Aligos Therapeutics Inc stockMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - The Globe and Mail
Aligos Therapeutics (ALGS) appoints Nikhil Aneja as new Principal Accounting Officer - Stock Titan
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos reports progress on Phase 2 hepatitis B drug study By Investing.com - Investing.com Australia
Aligos Therapeutics stock rises on Phase 2 HBV study progress By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Investing News Network
ALGS Executive Vice President and Chief Medical Officer Resigns - GuruFocus
Aligos Therapeutics (ALGS) Updates on Phase 2 Study for Hepatitis B Treatment - GuruFocus
Aligos reports progress on Phase 2 hepatitis B drug study - Investing.com
Aligos Therapeutics provides phase 2 B-SUPREME study progress updates - marketscreener.com
Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates - marketscreener.com
ALGS: Piper Sandler to Host Virtual Meeting on January 22 - GuruFocus
Lobbying Update: $80,000 of ALIGOS THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
(ALGS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market - TipRanks
Aligos therapeutics appoints James Hassard as chief commercial officer By Investing.com - Investing.com Nigeria
Geopolitics Watch: Why retail investors favor Aligos Therapeutics Inc stockPrice Action & Risk Controlled Daily Plans - Bộ Nội Vụ
Why retail investors favor Aligos Therapeutics Inc. stockInflation Watch & Verified Swing Trading Watchlist - Bộ Nội Vụ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Investing News Network
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos therapeutics appoints James Hassard as chief commercial officer - Investing.com India
Aligos Therapeutics strengthens senior leadership team with the appointment of James Hassard as executive vice president, chief commercial officer - marketscreener.com
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Investing News Network
Why Aligos Therapeutics Inc. stock could be next big winnerJuly 2025 Recap & Accurate Entry and Exit Point Alerts - ulpravda.ru
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Strong-Buy" - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stock2025 Market Trends & Community Consensus Trade Signals - Улправда
How resilient is Aligos Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Why analysts remain bullish on Aligos Therapeutics Inc. stockJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
2.25%
0.47%
자본화:
|
볼륨(24시간):